Fonseca F A, Novazzi J P, Cendoroglo M S, Duarte M, Almeida Pinto L E, Rabelo L M, da Rocha Martinez T L
Escola Paulista de Medicina-UNIFESP, Sö Paulo.
Arq Bras Cardiol. 1996 Jan;66(1):33-5.
To evaluate modifications on lipid profile, fibrinogen and platelet aggregation induced by etofibrate.
Twenty-one adult patients were studied. They all had primary hyperlipidemia and had already been on the AHA step I diet and placebo. Etofibrate (500mg/day) was administered for 60 days in the active phase, when lipid parameters, fibrinogen and platelet aggregation were measured.
The % significant reductions were: total cholesterol (-9.50%), LDL-cholesterol (-7.88%), triglycerides (-19.07%), total cholesterol/HDL-cholesterol(-11.90%), LDL-cholesterol/HDL-cholesterol (-10.20%), fibrinogen (-12.79%), platelet aggregation with adrenaline (-24.02%), with ADP 1 mumol (-30.13%), and ADP 3 mumol (-24.51%).
The beneficial effects of etofibrate were observed not only on the lipid profile but also on the thrombogenic parameters measured by fibrinogen and platelet aggregation.
评估益多酯对脂质谱、纤维蛋白原和血小板聚集的影响。
对21例成年患者进行研究。他们均患有原发性高脂血症，且已采用美国心脏协会第一步饮食方案并服用安慰剂。在活跃期给予益多酯（500毫克/天），持续60天，期间测量脂质参数、纤维蛋白原和血小板聚集情况。
显著降低的百分比分别为：总胆固醇（-9.50%）、低密度脂蛋白胆固醇（-7.88%）、甘油三酯（-19.07%）、总胆固醇/高密度脂蛋白胆固醇（-11.90%）、低密度脂蛋白胆固醇/高密度脂蛋白胆固醇（-10.20%）、纤维蛋白原（-12.79%）、肾上腺素诱导的血小板聚集（-24.02%）、1微摩尔二磷酸腺苷诱导的血小板聚集（-30.13%）以及3微摩尔二磷酸腺苷诱导的血小板聚集（-24.51%）。
观察到益多酯不仅对脂质谱有益，而且对通过纤维蛋白原和血小板聚集测量的血栓形成参数也有有益影响。
